Phase I/II clinical trial - Pédiatrie Tumeurs solides

iMATRIX-Alectinib (GO42286)
Pédiatrie Tumeurs solides
Ouvert depuis le: 01.24.2022
Site: Paris
Public cible
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.
Description de l'essai

This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.